Implications for Colorado on Federal Cannabis Reclassification

Senior Policy Advisor Mara Sheldon was featured in a Law Week Colorado Q&A on the federal government's decision to reclassify U.S. Food and Drug Administration (FDA)-approved and state‑licensed medical cannabis as a Schedule III substance and the implications for operators, particularly in Colorado. She clarified that though the change stops short of federal legalization – a common misconception – it represents a consequential development for licensed medical cannabis businesses by reducing Section 280E tax constraints and encouraging medical research. Ms. Sheldon also observed that the shift will likely benefit established operators first and encourage more deliberate investment and consolidation, but leave challenges such as banking access, interstate commerce and the broader state‑federal divide unresolved. In addition, she contended, the development adds credence to Colorado's yearslong process to license, track and regulate cannabis markets.

"This is the first time federal policy is really acknowledging the regulatory sophistication of state medical cannabis programs," she said.

READ: Implications for Colorado on Federal Cannabis Reclassification (Subscription required)